neovascular age-related macular degeneration
Coverage of neovascular age-related macular degeneration in the Nexus archive.
- Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration
Gene therapy for neovascular age-related macular degeneration (nAMD) showed stable vision and retinal anatomy for up to 5 years, with significant reductions in treatment burden, according to studies presented in Montreal.
- Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF
Pegcetacoplan (Syfovre), a complement inhibitor, showed similar efficacy in treating geographic atrophy (GA) whether administered to patients with concurrent neovascular age-related macular degeneration (nAMD) or to those with GA alone. The findings are based on data from a retina clinical trial.
- Loss of Payment Assistance for AMD Drugs Strains Patients and Ophthalmologists
Loss of copayment assistance for drugs treating neovascular age-related macular degeneration (nAMD) disrupted patient care, leading to shifts in therapy and reliance on samples. Patients and ophthalmologists face challenges due to the financial strain.